Shares of Moderna Inc. MRNA,
on Friday they fell 0.9% in pre-market trade after the company said it was pursuing the approval of the COVID-19 vaccine in Japan in collaboration with Takeda Pharmaceutical Co. 4502,
Takeda submitted the new drug application and will be responsible for importing and distributing the vaccine from the Cambridge, Massachusetts-based company. Takeda is also conducting the 1/2 phase vaccine trial in adults who are at least 20 years old; registration ended in February. If approved, Takeda will distribute 50 million doses of Moderna’s two-dose vaccine in Japan during the first half of 2021. Moderna’s shares have risen 372.3% over the past twelve months, while the S&P 500 Wider SPX,
increases by 20.4%.